论文部分内容阅读
目的评价贝伐珠单抗治疗复发恶性脑胶质瘤的疗效及不良反应。方法回顾性分析36例接受过贝伐珠单抗单药或联合化疗治疗的复发恶性脑胶质瘤患者的临床资料并进行生存随访,所有患者既往均接受过手术、放疗联合替莫唑胺化疗后肿瘤复发进展。按神经肿瘤疗效评价标准评价客观疗效,Kaplan-Meier法行生存分析,不良反应评价按CTC 3.0版标准。结果 36例患者的客观有效率为58.3%,中位无进展生存时间为4个月,中位总生存时间为7个月。主要不良反应有高血压、肝功能损害和骨髓抑制,无颅内出血、血栓、胃肠穿孔等严重不良反应。结论贝伐珠单抗治疗复发恶性脑胶质瘤客观有效率高,可以延长患者生存时间,毒性可耐受。
Objective To evaluate the efficacy and adverse reactions of bevacizumab in the treatment of recurrent malignant glioma. Methods The clinical data of 36 patients with recurrent malignant glioma who were treated with bevacizumab monotherapy or combined with chemotherapy were retrospectively analyzed and followed up for survival. All patients were previously treated with surgery and radiotherapy combined with temozolomide chemotherapy for tumor recurrence progress. According to the evaluation criteria of neurogenic tumor efficacy objective evaluation, Kaplan-Meier survival analysis, adverse reaction evaluation according to CTC 3.0 version. Results The objective response rate of 36 patients was 58.3%. The median progression-free survival time was 4 months and the median overall survival time was 7 months. The main adverse reactions were hypertension, liver damage and bone marrow suppression, no intracranial hemorrhage, thrombosis, gastrointestinal perforation and other serious adverse reactions. Conclusion Bevacizumab treatment of recurrent malignant gliomas objective and efficient, can extend the survival time of patients, toxicity can be tolerated.